Core Viewpoint - The company TianKang (301263.SZ) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd. (referred to as "Huabo Kaisheng"), has received a drug registration certificate from the National Medical Products Administration for Finasteride and Tadalafil Capsules, making it the first company in China to obtain this certification [1]. Group 1 - Huabo Kaisheng is the first company in China to receive a drug registration certificate for Finasteride and Tadalafil Capsules [1]. - The drug is a combination formulation consisting of Finasteride, a 5α-reductase inhibitor, and Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, specifically designed to treat symptoms of benign prostatic hyperplasia (BPH) [1]. - The combination of these two components provides a synergistic therapeutic effect, with Finasteride reducing prostate volume and alleviating urinary difficulties, while Tadalafil directly relieves lower urinary tract symptoms associated with BPH [1].
泰恩康(301263.SZ)子公司收到非那雄胺他达拉非胶囊药品注册证书